BSECompany UpdateMgmt Change1 Oct 2026
SYNCOM FORMULATIONS (INDIA) LIMITED
SYNCOM FORMULATIONS (INDIA) LIMITED has informed BSE about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent.<p><b>Details are as under:</b></p>
<table width="100%" border="0" cellspacing="0" cellpadding="0">
<tbody>
<tr>
<td bgcolor="#d6d6d6"><table border="0" cellpadding="4" cellspacing="1" width="100%">
<tbody>
<tr><td width="250" class="TTRow_left"> </td><td class="TTRow_left"><b> Details</b></td></tr>
<tr><td ....
Syncom Formulations (India) Limited has informed BSE about the appointment of an Executive Director.
BSECompany UpdateMgmt Change1 Oct 2026
SYNCOM FORMULATIONS (INDIA) LIMITED
SYNCOM FORMULATIONS (INDIA) LIMITED has informed BSE about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent.<p><b>Details are as under:</b></p>
<table width="100%" border="0" cellspacing="0" cellpadding="0">
<tbody>
<tr>
<td bgcolor="#d6d6d6"><table border="0" cellpadding="4" cellspacing="1" width="100%">
<tbody>
<tr><td width="250" class="TTRow_left" > </td><td class="TTRow_left"><b> Details</b></td></tr>
<tr><td ....
Syncom Formulations (India) Limited has informed BSE about the re-appointment of a Non-Executive Independent Director.
BSECompany UpdateMgmt Change1 Oct 2026
SYNCOM FORMULATIONS (INDIA) LIMITED
SYNCOM FORMULATIONS (INDIA) LIMITED has informed BSE about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent.<p><b>Details are as under:</b></p>
<table width="100%" border="0" cellspacing="0" cellpadding="0">
<tbody>
<tr>
<td bgcolor="#d6d6d6"><table border="0" cellpadding="4" cellspacing="1" width="100%">
<tbody>
<tr><td width="250" class="TTRow_left"> </td><td class="TTRow_left"><b> Details</b></td></tr>
<tr><td ....
Syncom Formulations (India) Limited has informed BSE about the appointment of an Executive Director.
BSECompany UpdateMgmt Change1 Oct 2026
SYNCOM FORMULATIONS (INDIA) LIMITED
SYNCOM FORMULATIONS (INDIA) LIMITED has informed BSE about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent.<p><b>Details are as under:</b></p>
<table width="100%" border="0" cellspacing="0" cellpadding="0">
<tbody>
<tr>
<td bgcolor="#d6d6d6"><table border="0" cellpadding="4" cellspacing="1" width="100%">
<tbody>
<tr><td width="250" class="TTRow_left"> </td><td class="TTRow_left"><b> Details</b></td></tr>
<tr><td ....
Syncom Formulations (India) Limited has informed BSE about the appointment of an Executive Director.
BSECompany UpdateMgmt Change1 Oct 2026
SYNCOM FORMULATIONS (INDIA) LIMITED
SYNCOM FORMULATIONS (INDIA) LIMITED has informed BSE about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent.<p><b>Details are as under:</b></p>
<table width="100%" border="0" cellspacing="0" cellpadding="0">
<tbody>
<tr>
<td bgcolor="#d6d6d6"><table border="0" cellpadding="4" cellspacing="1" width="100%">
<tbody>
<tr><td width="250" class="TTRow_left" > </td><td class="TTRow_left"><b> Details</b></td></tr>
<tr><td ....
Syncom Formulations (India) Limited has informed BSE about the re-appointment of a Non-Executive Independent Director.
BSECompany UpdateMgmt Change1 Oct 2026
Syncom Formulations India Ltd-$
Disclosure under reg 30 of SEBI (LODR) reg 2015 read with sub clause 7 of para A of part A of schedule /// change in directorate.
Syncom Formulations India Ltd has announced the appointment of two new directors, Rahul Vijay Bankda as Managing Director and Rinki Ankit Bankda as Whole Time Director, and the re-appointment of Ruchi Jindal as Woman Independent Director, following the approval of the 38th Annual General Meeting.
BSEAGM/EGMResults1 Oct 2026
Syncom Formulations India Ltd-$
Outcome of 38th AGM
Syncom Formulations India Ltd has announced the outcome of its 38th Annual General Meeting (AGM), where shareholders approved various resolutions, including the adoption of audited financial statements, declaration of a 10% dividend, and appointment of new directors.
BSEAGM/EGMMgmt Change1 Oct 2026
Syncom Formulations India Ltd-$
Declaration of Voting result as per regulation 44(3) of SEBI (LODR) regulation 2015.
Syncom Formulations India Ltd has declared the voting results of its 38th Annual General Meeting, where 10 resolutions were passed, including the re-appointment of a director and the declaration of a 10% dividend on its equity shares.
BSEAGM/EGMResults1 Oct 2026
Syncom Formulations India Ltd-$
Declaration of Result of Remote E Voting and E Voting at 38th AGM incompliance with Regulation 44(3) of SEBI (LODR) Regulation, 2015 in relation to 38th AGM of the company held on 30th September, 2026.
Syncom Formulations India Ltd has declared the results of its 38th Annual General Meeting, where 10 resolutions were passed, including the adoption of standalone and consolidated audited financial statements for the financial year ended March 31, 2026, and the declaration of a 10% dividend on 94 crore equity shares.
BSEAGM/EGM30 Sept 2026
Syncom Formulations India Ltd-$
Submission of proceedings of the 38th Annual General Meeting of the Company held on Wednesday, 30th September, 2026 pursuant to Regulation 30(2) read with Part A of Schedule /// of the SEBI (LODR) Regulation, 2015.
Syncom Formulations India Ltd has submitted the proceedings of its 38th Annual General Meeting held on September 30, 2026, through video conferencing. The meeting was attended by 73 members, exceeding the minimum quorum requirement.
BSECorp ActionDividend26 Sept 2026
Syncom Formulations India Ltd-$
Intimation under Regulation 30 of SEBI(LODR) Regulation 2015, Voluntary Waiver/Forgoing of Final Dividend by Promoter/Promoter Group.
Syncom Formulations India Ltd has announced that its promoters have voluntarily waived their entitlement to receive the final dividend proposed for the financial year ended 31st March 2026.
BSEInsider Trading / SASTRegulatory24 Sept 2026
Syncom Formulations India Ltd-$
We would like to inform you that Pursuant to the provisions of SEBI (PIT) Regulation, 2015. The window for dealing in the securities of the company shall remain closed from 1st Oct, 2026 and shall remain closed until 48 hours after the declaration of Unaudited Standalone & Consolidated Financial Results of the company for the quarter and half year ended on 30th September, 2026.
Syncom Formulations India Ltd has announced the closure of its trading window from 1st October 2026 until 48 hours after the declaration of its unaudited standalone and consolidated financial results for the quarter and half year ended 30th September 2026.
BSECompany UpdateResults1 Sept 2026
Syncom Formulations India Ltd-$
Submission of copy of newspaper clippings of notice of 38th Annual General Meeting (AGM), Remote E-Voting, Book Closure and other details.
Syncom Formulations India Ltd submits copy of newspaper clippings of Notice of 38th Annual General Meeting (AGM), Remote E-Voting, Book Closure and other details.
BSECompany UpdateResults12 Aug 2026
Syncom Formulations India Ltd-$
Submission of Press Clipping Related to extract of Un-Audited Standalone and Consolidated Financial Result for the Quarter ended on 30th June, 2026.
Syncom Formulations India Ltd submits press clipping related to un-audited standalone and consolidated financial results for the quarter ended June 30, 2026.
BSECompany UpdateMgmt Change11 Aug 2026
Syncom Formulations India Ltd-$
Disclosure under Regulation 30(2) read with Clause 7 of Para A of Schedule /// of the SEBI (LODR) Regulation, 2015: Change in directors, KMP and Senior Management.
Syncom Formulations India Ltd announced changes in its management, including the resignation of three directors and the appointment of two new directors. The resigning directors are Shri Kedarmal Shankarlal Bankda, Shri Vijay Shankarlal Bankda, and Shri Rahul Vijay Bankda. The new directors appointed are Smt. Rinki Ankit Bankda and Shri Ankur Vijay Bankda. The changes are effective from August 11, 2026, and August 12, 2026, respectively.
BSECompany Update11 Aug 2026
Syncom Formulations India Ltd-$
Corporate Announcement/Information pursuant to Regulation 44 of the SEBI (LODR) Regulation, 2015 regarding providing Remote E-Voting facilities for the 38th Annual General Meeting to be ....
Syncom Formulations India Ltd has announced the provision of Remote E-Voting facilities for its 38th Annual General Meeting to be held on 30th September, 2026.
BSECompany UpdateMgmt Change11 Aug 2026
Syncom Formulations India Ltd-$
Appointment of Cost Auditor and Internal Auditor for the FY 2026-27.
Syncom Formulations India Ltd has appointed M/s M. Goyal & Co. Cost Accountants as the Cost Auditor and M/s Bansal & Agrawal as the Internal Auditor for the financial year 2026-27.
BSEResultResults11 Aug 2026
Syncom Formulations India Ltd-$
Pursuant to Regulation 33(3) of SEBI (LODR) Regulations, 2015, we are pleased to submit the Un-Audited Standalone and Consolidated Financial Results along with Limited Review Report thereon ....
Syncom Formulations India Ltd has announced its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, with revenue from operations at Rs. 12,465.95 lakhs and profit before exceptional items and tax at Rs. 3,190.88 lakhs.
BSECorp. ActionDividend11 Aug 2026
Syncom Formulations India Ltd-$
We are pleased to inform you that, pursuant to the provision of Regulation 42 of SEBI (LODR) Regulations, 2015 and Section 91 of the Companies Act, 2013 the "Record Date" has been fixed ....
Syncom Formulations India Ltd has announced the fixing of record date for determining the entitlement of members for payment of dividend at the rate of 10% for the financial year 2025-26, subject to approval by the members at their ensuing 38th Annual General Meeting.
BSEBoard MeetingResults11 Aug 2026
Syncom Formulations India Ltd-$
Outcome of the 2/2026-27 Meeting of the Board of Directors of the Company held on Tuesday, 11th August 2026 pursuant to Regulation 30 read with Schedule III(A)(IV) of the SEBI(LODR) Regulations, 2015.
Syncom Formulations India Ltd's board meeting outcome announced, with approval of unaudited financial results, limited review report, and other business matters. Resignations of directors and appointments of new directors and CFO. Final dividend recommendation and record date set.